Profile data is unavailable for this security.
About the company
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
- Revenue in EUR (TTM)684.60m
- Net income in EUR127.00m
- Incorporated2006
- Employees2.43k
- LocationBiotest AGLandsteinerstr. 5DREIEICH 63303GermanyDEU
- Phone+49 61038010
- Fax+49 6 103801150
- Websitehttps://www.biotest.com/
More ▼
Holder | Shares | % Held |
---|---|---|
Arvernus Capital AGas of 30 Sep 2023 | 8.93k | 0.05% |
Banor Capital Ltd.as of 30 Nov 2021 | 4.45k | 0.02% |
BANTLEON Invest GmbHas of 30 Nov 2023 | 2.00k | 0.01% |
Norges Bank Investment Managementas of 31 Dec 2023 | 0.00 | 0.00% |
Axxion SA (Luxembourg)as of 31 Mar 2023 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.